Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
REGULATORY
Japan to Delete 16 Drugs from NHI Price List under New Streamlined Process
The Ministry of Health, Labor and Welfare (MHLW) will remove a total of 16 products from the NHI price list under a new streamlined delisting process. The delisting is expected to take place next April following a transitional period. The…
To read the full story
Related Article
- First Drug Delisting in Simplified Process Slated for March-End 2026: MHLW
September 10, 2024
- MHLW Announces Simplified New Process for Drug Delisting
August 19, 2024
- How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
- Simplified Delisting to Be Allowed for Generics with Low Market Share from September: MHLW
May 13, 2024
- MHLW Proposes Simplified Generic Delisting Scheme
April 22, 2024
- Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
REGULATORY
- Another LDP Study Group Submits Emergency Proposal Urging Drug Pricing Overhaul
December 5, 2025
- Ishin Urges Takaichi to Revisit OTC-Like Drug Coverage, Softens Savings Target
December 5, 2025
- JPMA Chief Presses LDP Study Group to Lock In On-Patent Prices, Scrap “Spillover” Rule
December 5, 2025
- LDP, Ishin to Continue OTC-Like Drug Talks on “Special Charge” Design
December 5, 2025
- Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…